Literature DB >> 29847204

Symptom Burden among Latino Patients with End-Stage Renal Disease and Access to Standard or Emergency-Only Hemodialysis.

Lilia Cervantes1,2, Madelyne Hull1, Angela Keniston1, Michel Chonchol2, Romana Hasnain-Wynia3, Stacy Fischer4.   

Abstract

BACKGROUND: Patients with end-stage renal disease (ESRD) have a high symptom burden and this negatively impacts health-related quality of life. Little is known about the symptom burden of Latinos with ESRD and variable access to hemodialysis.
OBJECTIVE: To estimate the symptom burden of Latinos with ESRD and access to standard or emergency-only hemodialysis. DESIGN/SETTING/
SUBJECTS: Observational descriptive study of Latino adults with ESRD receiving standard or emergency-only hemodialysis. Patients completed the Edmonton Symptom Assessment System Revised: Renal (ESAS-r:Renal). We used descriptive statistics and propensity score adjustment to conduct the analysis. MEASUREMENT: ESAS-r:Renal.
RESULTS: Participants (N = 67) had a mean age of 58 years (standard deviation [SD] ±13) and a mean Charlson Comorbidity Index of 6.6 ± 2.5, and had been on hemodialysis a mean of 42 months (SD ±43). On average, Latinos with ESRD experienced 7 (SD ±3) symptoms with a mean of 5 ± 3 symptoms reported as moderate or severe. After adjusting for propensity score, emergency-only hemodialysis patients reported experiencing more nausea compared to standard hemodialysis patients (odds ratio 8.95, 95% confidence interval: 1.17-68.31, p = 0.03).
CONCLUSION: Latinos with ESRD have a high symptom burden and compared to patients with standard hemodialysis, patients who rely on emergency-only hemodialysis report more nausea. A national treatment strategy that provides standard hemodialysis for undocumented immigrants with ESRD is an important next step.

Entities:  

Keywords:  Latino; end-stage renal disease; ethnic minority; health disparities; hemodialysis; quality of life

Mesh:

Year:  2018        PMID: 29847204     DOI: 10.1089/jpm.2017.0663

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  6 in total

1.  The Experience of Primary Caregivers of Undocumented Immigrants with End-Stage Kidney Disease that Rely on Emergency-Only Hemodialysis.

Authors:  Lilia Cervantes; Alaina L Carr; Christine C Welles; Jeff Zoucha; John F Steiner; Tracy Johnson; Mark Earnest; Claudia Camacho; Krithika Suresh; Romana Hasnain-Wynia
Journal:  J Gen Intern Med       Date:  2020-02-19       Impact factor: 5.128

Review 2.  Hemodialysis care for undocumented immigrants with end-stage renal disease in the United States.

Authors:  Christine C Welles; Lilia Cervantes
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-11       Impact factor: 3.416

3.  Perspectives on Kidney Disease Education and Recommendations for Improvement Among Latinx Patients Receiving Emergency-Only Hemodialysis.

Authors:  Tessa K Novick; Santiago Diaz; Francisco Barrios; Doris Cubas; Kavyaa Choudhary; Paul Nader; Raymonda ElKhoury; Lilia Cervantes; Elizabeth A Jacobs
Journal:  JAMA Netw Open       Date:  2021-09-01

4.  Emergency department visits for hemodialysis by insurance status in the United States.

Authors:  Julianna West; Hei Kit Chan; Henry Wang; Donald Molony; John Foringer; Ryan Huebinger; David Robinson; Summer Chavez
Journal:  J Am Coll Emerg Physicians Open       Date:  2022-04-19

5.  The Suffering of Advanced Chronic Renal Patients and Their Relationship with Symptoms in Loja, Ecuador.

Authors:  Patricia Bonilla-Sierra; Ana Magdalena Vargas-Martínez; Fatima Leon-Larios; Joselin Valeria Arciniega Carrión; Tatiana Cecibel Jiménez Alverca; María de Las Mercedes Lomas-Campos; José Rafael González-López
Journal:  Int J Environ Res Public Health       Date:  2021-05-16       Impact factor: 3.390

6.  Dialysis Care for Undocumented Immigrants With Kidney Failure in the COVID-19 Era: Public Health Implications and Policy Recommendations.

Authors:  Katherine Rizzolo; Tessa K Novick; Lilia Cervantes
Journal:  Am J Kidney Dis       Date:  2020-05-12       Impact factor: 8.860

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.